BTIG analyst Ryan Zimmerman reiterated a Neutral rating on Vericel Corporation (NASDAQ:VCEL) on Wednesday while the firm examines growth prospects for MACI, the company's flagship product. The stock trades at $57.88, sitting 3% below its 52-week high of $59.75 and up 66% over the past six months.

BTIG's fiscal 2027 MACI estimate of $340.0 million, representing 16.8% year-over-year growth, falls $4.3 million below consensus estimates of $344.3 million. The firm's fiscal 2026 estimate of $291.1 million aligns with consensus expectations of $291.0 million.

MACI posted growth exceeding 20% for six consecutive quarters, with October marking the strongest biopsy month since launch. Vericel's overall revenue growth reached 25% over the last twelve months with a gross profit margin of 74%.

BTIG's analysis indicates consensus estimates would require approximately 9.5% implant growth combined with an 800 basis point price increase, or 12.6% volume growth with a 500 basis point price increase. The firm noted consensus appears achievable if conversion holds in the low 30% range and pricing stays in the mid-single to high-single digit range, but becomes more challenging if conversion declines toward 30%.

Management stated conversion "remains on track" heading into fiscal 2027 without indicating an uptick. Management previously called consensus estimates "a good starting point" for fiscal 2027.

In third-quarter 2026 results, Vericel reported earnings of $0.27 per share and revenue of $85.37 million, both surpassing Wall Street forecasts. Earnings exceeded the consensus estimate of $0.06 per share by 350%, while revenue surpassed expectations by approximately 9.5%. Revenue increased 26% compared to the prior year period. Following these results, Truist Securities raised its price target for Vericel to $65 from $52, maintaining a Buy rating.